Iontophoresis and Sonophoresis in Drug Delivery: A Potential Alternative to Oral and Injectable Routes

Sourabh khade[1], Anuj Yadav[2], Pushkar Vishwakarma[3*]

[1,2] Postgraduate students at IPS academy college of pharmacy, A.B Road, Rajendra Nagar, Indore (M.P) 452012

[3*] Postgraduate students at Kalinga University, Naya Raipur, (C.G) 492101

Abstract

Iontophoresis and sonophoresis are emerging non-invasive transdermal drug delivery techniques that enhance drug permeation using electrical current and ultrasound waves, respectively. This review explores their mechanisms, pharmaceutical applications, clinical efficacy, and regulatory challenges while highlighting recent innovations such as nanocarriers, microneedles, and smart transdermal patches. Iontophoresis is effective for charged and hydrophilic drugs, whereas sonophoresis facilitates the absorption of both hydrophilic and lipophilic compounds. Clinical studies support their use in pain management, hormone therapy, dermatology, and ocular drug delivery, though standardization and regulatory hurdles remain. Future advancements in wearable technologies and combination therapies may further enhance their therapeutic potential.

Keywords: Iontophoresis, Sonophoresis, Transdermal drug delivery, Nanotechnology, Smart patches, Microneedles.

1. Introduction

Effective drug delivery is essential to ensuring that therapeutic agents reach their target sites with optimal efficacy and minimal side effects. Traditional drug administration methods, such as oral and injectable routes, have been widely used but pose several challenges. Oral drug delivery often suffers from poor bioavailability due to enzymatic degradation in the gastrointestinal tract and hepatic first-pass metabolism, leading to reduced therapeutic efficiency [1]. Furthermore, certain drugs, particularly peptides and proteins, degrade rapidly in the digestive system and thus require alternative delivery mechanisms [2].

Injectable drug administration, while ensuring rapid systemic drug availability, has notable drawbacks such as pain, risk of infection, the need for trained medical personnel, and potential patient non-compliance [3]. Frequent injections can also result in tissue damage, hypersensitivity reactions, and an increased risk of needle-stick injuries among healthcare workers [4].

1.1 Need for Alternative Drug Delivery Systems

To overcome the limitations of conventional drug delivery methods, researchers have focused on developing innovative non-invasive techniques. Transdermal drug delivery [TDD] has emerged as a promising alternative by enabling direct systemic drug absorption while bypassing the gastrointestinal tract [5]. However, the outermost layer of the skin, the stratum corneum, acts as a formidable barrier, restricting the penetration of most drugs [6].

Various physical enhancement techniques, including iontophoresis and sonophoresis, have been developed to improve transdermal drug permeation [7]. These approaches offer a controlled, non-invasive means of delivering both hydrophilic and lipophilic drugs, including macromolecules such as peptides and proteins, which typically require injectable administration [8].

1.2 Role of Iontophoresis and Sonophoresis in Transdermal Drug Delivery

1.Iontophoresis: Drug Delivery Using Electrical Current

Iontophoresis is a transdermal drug delivery technique that employs a low-intensity electrical current to drive ionized drug molecules through the skin [9].

1. Precise Dose Control: The drug delivery rate can be adjusted by modulating the electrical current intensity and duration.
2. Reduced Systemic Side Effects: Unlike oral and injectable routes, iontophoresis enables localized drug delivery, minimizing systemic toxicity.
3. Minimally Invasive Nature: It provides a needle-free alternative for administering peptides, local anesthetics, and pain medications [10].

Iontophoresis has been investigated for applications such as transdermal insulin delivery in diabetic patients, local anesthesia administration, and the controlled release of anti-inflammatory drugs [11]. Recent studies have also explored its potential for delivering chemotherapeutic agents transdermal, reducing the need for intravenous injections [12].

2. Sonophoresis: Drug Delivery Using Ultrasound

Sonophoresis, also known as phonophoresis, employs ultrasound waves to enhance drug permeation through the skin by temporarily disrupting the stratum corneum’s lipid structure [13].

The primary mechanisms of sonophoresis include:

1. Cavitation: Formation and collapse of microscopic bubbles in the intercellular lipid layer, creating microchannels for drug penetration.

2. Acoustic Streaming: Movement of skin fluids that enhances drug diffusion across the dermal layers.
3. Thermal Effects: Mild heating caused by ultrasound application increases skin permeability by loosening lipid bilayers [14].

Sonophoresis has been widely studied for transdermal drug delivery applications, including pain management [topical NSAIDs], hormone replacement therapy [transdermal estrogen and testosterone], and the delivery of systemic drugs such as insulin [15]. Additionally, combining sonophoresis with other enhancement methods, such as iontophoresis and microneedles, has been shown to significantly improve drug penetration [16].

Recent advancements in transdermal drug delivery suggest that combining iontophoresis and sonophoresis can further enhance drug absorption efficiency. Studies indicate that the simultaneous application of ultrasound and an electric current significantly improves drug permeation compared to using each technique independently [17].

The future of transdermal drug delivery lies in optimizing these technologies for clinical application. The development of wearable iontophoretic patches and portable sonophoresis devices is being explored to facilitate patient-centered drug administration [18]. Additionally, ongoing research aims to expand the range of transdermal deliverable drugs, particularly biologics such as monoclonal antibodies and RNA-based therapeutics [19,20].

2. The Skin as a Barrier to Drug Delivery

2.1 Structure and Function of the Skin

The skin is the largest organ of the human body, primarily functioning as a protective barrier against external physical, chemical, and microbial insults. It consists of three main layers: the epidermis, dermis, and hypodermis. The epidermis, the outermost layer, is the primary barrier to drug penetration, primarily due to its stratum corneum [SC], a highly ordered lipid matrix embedded with corneocytes [21]. This layer is hydrophobic and restricts the penetration of hydrophilic and large molecular weight drugs. Below it, the viable epidermis and dermis provide additional selective permeability and metabolic activity, while the hypodermis provides structural support and houses blood vessels that facilitate systemic absorption of drugs [22].

Key Features of the Skin Barrier

1. The stratum corneum has a "brick-and-mortar" structure, where corneocytes [bricks] are surrounded by lipid bilayers [mortar], limiting passive drug diffusion [23].
2. Epidermal enzymes, including esterases, peptidases, and oxidases, can degrade drugs before they reach systemic circulation [24].

3. The dermis contains capillaries that can transport drugs into the bloodstream if they penetrate deeply enough [25].

2.2 Limitations of Conventional Transdermal Drug Delivery

Barriers to Transdermal Drug Absorption

1. Molecular Size and Hydrophobicity: Only small [<500 Da] and lipophilic drugs passively diffuse through the SC [26].
2. Low Permeability Coefficient: The SC's highly structured lipids limit the passive diffusion of most therapeutic compounds [27].
3. Metabolic Activity of the Skin: Drug-metabolizing enzymes in the epidermis can degrade drugs before absorption [28].
4. Inter-individual Variability: Age, hydration, ethnicity, and anatomical site influence drug penetration **[29].**
5. Limited Drug Reservoir Capacity: Only a few milligrams of a drug can be delivered transdermally, limiting its use for high-dose therapies [30].

2.3 Strategies to Enhance Skin Permeability

Chemical Enhancement Strategies

1. Lipophilic Permeation Enhancers: Fatty acids [e.g., oleic acid] and alcohols disrupt lipid bilayers, improving drug diffusion [31].
2. Surfactants and Cyclodextrins: Reduce SC lipid order and improve drug solubilization [32].
3. Iontophoresis and Sonophoresis: Utilize electric fields and ultrasound waves to temporarily alter skin permeability [33].

Physical Enhancement Techniques

1. Microneedles: Create microchannels that bypass the SC barrier without causing pain or irritation [34].
2. Electroporation: Uses high-voltage pulses to create transient aqueous pores in the SC [35].
3. Thermal Ablation: Uses controlled heat to disrupt the SC, enhancing hydrophilic drug delivery [36].

Biological Enhancement Strategies

1. Nanoparticle-based Delivery Systems: Liposomes, ethosomes, and solid lipid nanoparticles facilitate drug penetration [37].
2. Enzyme Inhibitors: Block epidermal enzymes that degrade drugs before absorption [38].

3. Fundamentals of Iontophoresis in Drug Delivery

Iontophoresis is a non-invasive technique used to enhance the transdermal transport of charged drug molecules by applying a low electrical current. This method is particularly beneficial for delivering hydrophilic and charged drugs, which would otherwise face significant barriers crossing the stratum corneum, the outermost layer of the skin. Iontophoresis operates based on electrochemical principles, utilizing an anode and a cathode to drive ionized molecules into the skin through electrostatic repulsion. The current applied typically ranges from 0.1 to 0.5 mA/cm^2, ensuring controlled and sustained drug release [39].

The mechanism allows for precise dosing and eliminates common limitations associated with oral and injectable routes, such as first-pass metabolism and patient discomfort. Unlike passive transdermal drug delivery, iontophoresis actively propels drugs into systemic circulation or localized tissues, making it an effective strategy for administering macromolecular drugs like peptides and proteins [40,41].

3.1 Mechanisms of Iontophoresis

1. Electro-repulsion [Nernst–Planck effect]: The main driving force in iontophoresis, electro-repulsion occurs when charged drug molecules experience direct repulsion from an electrode of the same charge. For example, positively charged drugs are repelled by the anode and move through the skin into the body [42].
2. Electro-osmosis: This secondary mechanism involves the movement of solvent [water] through the skin due to an applied electric field. The skin, having a net negative charge at physiological pH, facilitates convective transport from the anode to the cathode, enhancing the delivery of neutral or weakly charged drugs [43].
3. Increased skin permeability: The electrical current applied during iontophoresis disrupts the skin's lipid bilayers, temporarily enhancing permeability. This effect allows larger drug molecules to penetrate the skin more efficiently than in passive transdermal systems [44].

3.2 Factors Influencing Iontophoresis Efficacy

1. Drug Properties: The molecular weight, charge, and solubility of a drug influence its transport. Generally, molecules under 500 Da with high aqueous solubility demonstrate superior iontophoretic permeability [45].
2. Current Strength and Duration: The efficiency of drug transport is proportional to the intensity of the applied current. However, excessive current [>0.5 mA/cm²] can cause skin irritation or burns, necessitating optimized parameters to balance efficacy and patient comfort [46].
3. Electrode Design: The composition and positioning of electrodes impact drug delivery efficiency. Silver-silver chloride [Ag/AgCl] electrodes are commonly used due to their stability and ability to minimize unwanted electrochemical reactions [47].
4. Skin Hydration and Condition: Hydrated skin exhibits lower electrical resistance, facilitating improved drug penetration. However, damaged or keratinized skin may reduce iontophoretic efficiency [48].

3.3 Applications in Drug Delivery

1. Local Anesthesia: Iontophoretic delivery of lidocaine provides rapid pain relief for dermatological and minor surgical procedures without the need for injections [49].
2. Transdermal Insulin Delivery: Iontophoresis has been studied as a non-invasive alternative for insulin administration in diabetes management, showing promising results in preclinical and clinical trials [50].
3. Ophthalmic Drug Delivery: Iontophoresis enhances the corneal penetration of antibiotics and anti-inflammatory agents, offering a targeted approach for treating ocular infections [51].
4. Dermatological Treatments: It is widely used in treating hyperhidrosis [excessive sweating] and psoriasis, improving drug penetration and therapeutic outcomes [52].
5. Musculoskeletal Disorders: Iontophoresis facilitates the localized delivery of corticosteroids, such as dexamethasone, for treating inflammatory conditions like tendinitis and arthritis [53,54].

4. Fundamentals of Sonophoresis in Drug Delivery

Sonophoresis, also referred to as phonophoresis, is a non-invasive drug delivery technique that utilizes ultrasound waves to facilitate the transdermal transport of drugs. This method has gained attention as a viable alternative to conventional oral and injectable routes, particularly for drugs with poor skin permeability [55]. The fundamental working principle of sonophoresis involves the

application of ultrasonic energy to the skin, which temporarily alters the structure of the stratum corneum, the outermost barrier of the skin, allowing for enhanced drug penetration [56].

Typically, ultrasound frequencies ranging from 20 kHz to 16 MHz are employed in sonophoresis, with lower frequencies [20–100 kHz] demonstrating greater efficacy in enhancing drug delivery due to their ability to induce pronounced mechanical effects on the skin [57]. The effectiveness of this technique is influenced by ultrasound parameters such as frequency, intensity, and duty cycle, as well as the physicochemical properties of the drug and formulation [58].

4.1 Mechanisms of Sonophoresis

The enhanced drug permeation achieved through sonophoresis is primarily attributed to three key mechanisms: cavitation, thermal effects, and microstreaming.[59,60,61]

1.Cavitation: Cavitation is a major contributor to the sonophoretic effect and refers to the formation, expansion, and collapse of microscopic bubbles within the medium due to ultrasound waves [59]. This phenomenon generates localized mechanical stress on the skin, disrupting lipid bilayers in the stratum corneum and creating transient aqueous channels that facilitate drug transport [60]. Studies have shown that cavitation-driven sonophoresis significantly enhances the permeability of both hydrophilic and hydrophobic drugs [61].

2.Thermal Effects: Ultrasound application generates localized heating, which increases the kinetic energy of skin lipids, leading to temporary disorganization of the stratum corneum structure [62]. This enhances drug diffusion by reducing the resistance of the skin barrier. The extent of the thermal effect depends on ultrasound intensity and exposure duration, with higher intensities **[**≥2 W/cm²**]** promoting greater permeability enhancement [63]. However, excessive heating can cause skin irritation or tissue damage, necessitating careful optimization of parameters [64].

3.Microstreaming: Microstreaming refers to the formation of microscale fluid currents induced by ultrasonic waves. These currents facilitate the mixing of drug molecules in the application site, improving their penetration into the skin [65]. Additionally, microstreaming can enhance the diffusion of large macromolecules that would otherwise be hindered by the skin's tight junctions [66].

4.2 Factors Affecting Sonophoresis Efficacy

1. **Frequency and Intensity:** The frequency and intensity of ultrasound waves significantly impact the depth and extent of drug permeation. Low-frequency ultrasound [≤100 kHz] is more effective in enhancing transdermal drug transport due to its greater cavitation activity, while higher frequencies [≥1 MHz] primarily induce thermal effects [67]. The intensity of ultrasound

determines the energy delivered to the skin, with moderate intensities [0.5–2 W/cm²] being optimal for transdermal drug enhancement without causing excessive skin irritation [68].

2. **Drug Formulation:** The physicochemical properties of the drug and its formulation play a crucial role in determining its suitability for sonophoretic delivery. Hydrophilic drugs tend to benefit more from ultrasound-enhanced permeation compared to hydrophobic compounds due to their ability to utilize aqueous channels created by cavitation [69]. Formulations incorporating penetration enhancers, such as surfactants and liposomes, further improve drug transport efficiency [70].
3. **Skin Hydration and Integrity:** Skin hydration enhances the efficacy of sonophoresis by facilitating cavitation and reducing the resistance of the stratum corneum [71]. Conversely, the presence of thickened or damaged skin may hinder drug absorption. Pre-treatment methods, such as occlusion or mild exfoliation, have been explored to improve sonophoretic drug delivery in cases of hyperkeratotic skin conditions [72].

4.3 Applications of Sonophoresis in Drug Delivery

1.**Localized Drug Delivery:** One of the primary applications of sonophoresis is the localized delivery of anti-inflammatory and analgesic agents. This technique has been widely utilized in physical therapy and dermatology for enhancing the penetration of corticosteroids, nonsteroidal anti-inflammatory drugs *[*NSAIDs*]*, and anesthetics into deeper tissue layers [73]. Sonophoretic drug delivery has demonstrated superior efficacy in conditions such as arthritis, tendinitis, and localized pain management [74].

2.**Systemic Drug Delivery:** Sonophoresis has shown promise in achieving systemic drug absorption via the transdermal route. Studies have explored its application for delivering insulin, hormones, and cardiovascular drugs, offering an alternative to injections for chronic disease management [75]. By optimizing ultrasound parameters and formulation design, researchers have achieved sustained plasma drug concentrations comparable to conventional administration routes [76].

3.Transdermal Immunization: Recent advancements in sonophoresis have extended its application to vaccine delivery. Low-frequency ultrasound has been investigated for facilitating the transdermal administration of protein-based vaccines, potentially eliminating the need for injections [77]. This approach holds promise for improving patient compliance and accessibility, particularly in mass immunization programs [78].

5. Comparative Analysis: Iontophoresis vs. Sonophoresis

Iontophoresis relies on an electric field to facilitate the movement of ionized drug molecules through the skin via electro-repulsion [also called the Nernst–Planck effect], electro-osmosis, and increased skin permeability [71]. The applied electric current causes charged drug molecules to migrate towards the opposite-charged electrode, allowing for targeted and controlled drug delivery. This method is particularly effective for delivering small, charged molecules, such as peptides and certain antibiotics, directly into systemic circulation or localized tissues [72].

Sonophoresis, on the other hand, utilizes ultrasound waves to create mechanical effects on the skin, enhancing permeability by disrupting lipid bilayers and forming aqueous channels in the stratum corneum. It operates through three primary mechanisms: cavitation [formation and collapse of microbubbles], thermal effects [localized heating that disrupts lipid structure], and microstreaming [fluid turbulence that enhances molecular transport] [73]. Sonophoresis is particularly effective for both hydrophilic and hydrophobic drugs, making it suitable for larger biomolecules like proteins and vaccines [74].

5.1 Drug Types Suitable for Each Technique

- Iontophoresis is most effective for small, ionized drugs [<500 Da] with high aqueous solubility [75]. Examples include local anesthetics [e.g., lidocaine], anti-inflammatory agents [e.g., dexamethasone], and peptides [e.g., insulin].
- Sonophoresis is more versatile, allowing the delivery of both hydrophilic and hydrophobic drugs, including large macromolecules [>500 Da] such as proteins, hormones, and vaccines [76]. It is particularly useful for dermatological drugs, pain management, and transdermal immunization.

Property	Iontophoresis	Sonophoresis
Ideal Drug Type	Small, charged molecules	Large, hydrophilic/hydrophobic drugs
Molecular Weight	<500 Da	>500 Da
Solubility	Water-soluble	Both water-soluble and lipid-soluble
Examples	Lidocaine, insulin, dexamethasone	Corticosteroids, proteins, vaccines

A comparison of drug compatibility is summarized in Table 1 below.

5.2 Advantages and Limitations of Both Methods

Advantages

1. Iontophoresis enables precise control over drug dosing due to its reliance on electric current, making it a highly targeted and reproducible method [77]. It is widely used for localized drug delivery in treating arthritis, hyperhidrosis, and localized infections.
2. Sonophoresis offers a broader range of drug compatibility, including hydrophobic molecules and macromolecular therapeutics. It is particularly advantageous for vaccine delivery and transdermal pain management without injections [78].

Limitations

1. Iontophoresis is limited by its dependence on drug charge—neutral and non-polar drugs cannot be delivered efficiently. Additionally, prolonged application can cause skin irritation or burns at high current densities [79].
2. Sonophoresis requires careful optimization of ultrasound frequency and intensity to avoid excessive thermal effects or tissue damage. It may also require formulation additives to enhance drug solubility and stability during sonophoretic treatment [80].

5.3 Synergistic Use of Iontophoresis and Sonophoresis

Recent studies have explored the combined use of iontophoresis and sonophoresis to maximize drug permeation. By applying ultrasound waves before iontophoresis, the stratum corneum can be pre-treated to enhance its permeability, allowing for increased electrophoretic transport of drugs [81]. This hybrid approach has been particularly effective for delivering peptides, pain medications, and topical corticosteroids [82].

Furthermore, combining both techniques has been shown to significantly improve drug retention in target tissues, reduce systemic side effects, and enable lower drug dosages while maintaining therapeutic efficacy [83].

6. Pharmaceutical Applications of Iontophoresis and Sonophoresis

1. Transdermal Drug Delivery: Transdermal drug delivery has gained prominence as a non-invasive alternative to oral and injectable administration. Iontophoresis and sonophoresis enhance drug penetration through the stratum corneum, overcoming the natural barrier properties of the skin. These techniques have been extensively explored for pain management, anti-inflammatory drugs, and hormone therapy.

2. Pain Management: Iontophoresis is widely used to deliver local anesthetics and analgesics such as lidocaine and fentanyl for pain relief [84]. The application of an electric current allows charged drug molecules to penetrate deeper layers of the skin, ensuring rapid onset of action. Sonophoresis, on the other hand, enhances drug permeation via acoustic cavitation, making it suitable for delivering NSAIDs and opioids through the skin without the need for injections [85].
3. Anti-inflammatory Drugs: Nonsteroidal anti-inflammatory drugs [NSAIDs] such as diclofenac and ketoprofen have shown increased transdermal absorption via iontophoresis due to electro-repulsion effects [86]. Similarly, sonophoresis has been investigated for its ability to enhance localized delivery of anti-inflammatory agents, particularly in rheumatoid arthritis and sports injuries [87].
4. Hormone Therapy: Transdermal hormone therapy has gained traction in treating endocrine disorders. Iontophoresis effectively delivers insulin, estradiol, and testosterone, offering a promising alternative to daily injections [88]. Sonophoresis has demonstrated potential for enhancing estradiol permeability, thereby improving therapeutic outcomes in hormone replacement therapy [HRT] [89].
5. Peptide and Protein Delivery: The delivery of large biomolecules, including peptides and proteins, is one of the major challenges in pharmaceutical sciences. Traditional oral administration is inefficient due to enzymatic degradation and poor gastrointestinal absorption. Iontophoresis and sonophoresis have emerged as effective strategies for non-invasive peptide and protein drug delivery.

Iontophoresis facilitates the transport of insulin, calcitonin, and growth hormone-releasing peptides by applying a controlled electric current, preventing enzymatic degradation and enhancing systemic absorption [90]. Sonophoresis, on the other hand, enhances skin permeability through cavitation effects, making it useful for delivering monoclonal antibodies and protein-based drugs [91].

6.1 Drug Delivery in Dermatology and Cosmeceuticals

Both iontophoresis and sonophoresis have found extensive applications in dermatological and cosmeceutical drug delivery. Iontophoresis is used to treat hyperhidrosis, acne, and hyperpigmentation, while sonophoresis has been extensively utilized in anti-aging treatments and the delivery of antioxidants [92].

Iontophoresis has been shown to increase the penetration of vitamin C, retinoids, and hydroquinone, making it a valuable technique in dermatology and cosmetic medicine [93]. Additionally, sonophoresis enhances the absorption of hyaluronic acid, peptides, and collagen, which are commonly used in skin rejuvenation therapies [94].

6.2 Ocular and Systemic Drug Delivery

1. Ocular Drug Delivery: Iontophoresis has been explored for the delivery of antibiotics, corticosteroids, and anti-glaucoma drugs, significantly enhancing intraocular penetration [95]. Sonophoresis, through the use of low-frequency ultrasound, has demonstrated improved permeation of cyclosporine, timolol, and dexamethasone, suggesting its potential for treating dry eye syndrome and glaucoma [96].
2. Systemic Drug Delivery: The ability of iontophoresis to transport charged molecules across biological membranes has led to its application in systemic drug delivery, including the administration of opioids, peptides, and cardiovascular drugs [97]. Sonophoresis, due to its ability to enhance vascular permeability, has been investigated for the transdermal delivery of chemotherapeutic agents and neuroactive compounds [98].

7. Clinical and Regulatory Perspectives

Over the years, iontophoresis and sonophoresis have evolved into clinically viable drug delivery methods, with several FDA-approved systems demonstrating safety and efficacy. Iontophoresis-based transdermal drug delivery is primarily used for localized pain relief, wound healing, and drug administration in dermatology, while sonophoresis is explored for enhanced transdermal transport of various therapeutics.

One of the first FDA-approved iontophoretic systems was Ionsys®, which delivers fentanyl for post-operative pain management, using a self-activated iontophoretic patch [99]. The Sumatriptan iontophoretic patch, used in migraine treatment, was another major regulatory milestone, proving iontophoresis as an effective alternative to traditional routes [100]. In sonophoresis, low-intensity continuous ultrasound [LICUS] has received regulatory approval for its role in bone regeneration and enhanced transdermal drug absorption [101]. However, despite promising clinical outcomes, the adoption of sonophoresis in mainstream medicine is less widespread than iontophoresis due to regulatory concerns and standardization challenges [102].

7.2 Clinical Trials and Efficacy Studies

Numerous clinical trials have evaluated the safety, efficacy, and pharmacokinetics of iontophoretic and sonophoretic systems. For instance, a randomized clinical trial on iontophoresis-delivered dexamethasone demonstrated its effectiveness in treating inflammatory conditions such as tendonitis and bursitis, with minimal systemic side effects [103]. Another double-blind study on sonophoresis-mediated insulin delivery showed that ultrasound-assisted transdermal insulin absorption could provide a non-invasive alternative to subcutaneous injections for diabetes management [104].

In dermatology, clinical research has demonstrated the efficacy of iontophoretic lidocaine patches for local anesthesia, significantly reducing pain in minor dermatological procedures [105]. Similarly, low-frequency sonophoresis [LFS] has been investigated for transdermal drug delivery of chemotherapy agents, with trials confirming enhanced permeability and reduced systemic toxicity [106]. Despite these successes, long-term clinical data and larger-scale trials are still required for regulatory bodies to broaden approvals of sonophoretic technologies in drug delivery [107].

7.3 Regulatory Challenges and FDA Approvals

1. Safety concerns – The potential for skin irritation and burns in iontophoresis and ultrasound-induced tissue damage in sonophoresis has raised regulatory concerns [108].
2. Standardization issues – Variability in drug formulations, device parameters, and patient response makes it difficult to set universal regulatory guidelines [109].
3. Lack of large-scale trials – Although small-scale studies indicate promising results, regulatory bodies require extensive clinical validation before approving new iontophoretic and sonophoretic drug formulations [110].
4. High costs – The development and approval of transdermal delivery devices require substantial investment, which limits the commercial viability of these technologies [111].

Recent advances, such as microneedle-enhanced sonophoresis and combination iontophoretic drug patches, are under active regulatory review for their potential to overcome these challenges [112].

8. Future Prospects and Innovations

8.1 Nanotechnology and Microfabrication in Iontophoresis and Sonophoresis

The integration of nanotechnology and microfabrication into iontophoretic and sonophoretic drug delivery systems has the potential to revolutionize transdermal therapy. Nanocarriers, including liposomes, nanoemulsions, and polymeric nanoparticles, have been widely studied for their ability to enhance drug solubility, stability, and controlled release [113]. These nanocarriers can be incorporated into iontophoresis and sonophoresis-based formulations to improve drug permeation and retention in the skin, reducing systemic side effects [114].

Microfabrication technologies, such as microelectromechanical systems [MEMS] and nanoelectrodes, have been explored to enhance the efficiency of iontophoretic devices. By miniaturizing electrodes and optimizing charge distribution, researchers have improved the precision and targeted delivery of charged molecules into the skin [115]. Similarly, microbubble-based sonophoresis has been introduced, where ultrasound waves interact with gas-filled microbubbles, increasing drug transport via cavitation effects [116].

8.2 Wearable and Smart Transdermal Patches

The development of wearable and smart transdermal patches represents a significant leap forward in non-invasive drug delivery. These devices integrate wireless technology, biosensors, and automated drug release mechanisms, enabling real-time monitoring and personalized dosing [117].

Recent advances have led to the creation of self-regulating iontophoretic patches that deliver drugs in response to physiological conditions, such as glucose levels in diabetic patients [118]. Similarly, wearable ultrasound patches are being developed to enhance sonophoretic drug penetration, allowing for continuous drug delivery over extended periods without the need for repeated application [119].

A promising example is the IontoPatch, a wireless iontophoretic system used for localized corticosteroid delivery in sports medicine and dermatology [120]. Additionally, wearable sonophoretic patches have been investigated for hormone therapy and pain management, demonstrating enhanced patient compliance compared to conventional drug administration methods [121].

8.3 Combination Therapies with Microneedles and Nano-Carriers

Combining iontophoresis and sonophoresis with microneedles and nano-carriers has shown significant promise in enhancing transdermal drug delivery efficiency. Microneedles create microchannels in the skin, reducing stratum corneum resistance, while iontophoresis and sonophoresis further drive drug molecules into deeper tissues without causing patient discomfort [122].

Recent studies have demonstrated that the combination of microneedles and iontophoresis improves the delivery of biologic drugs, including insulin, monoclonal antibodies, and vaccines [123]. Similarly, the integration of nanocarriers [such as lipid nanoparticles and polymeric hydrogels] with sonophoresis has enabled the targeted release of chemotherapy agents, reduced systemic toxicity and improved therapeutic outcomes in skin cancer treatments [124].

The future direction of transdermal therapy lies in multi-modal drug delivery systems that leverage iontophoresis, sonophoresis, microneedles, and nanocarriers to optimize drug absorption, reduce adverse effects, and improve treatment efficacy [125].

9. Conclusion

In conclusion, this review highlights that both iontophoresis and sonophoresis present promising avenues as alternatives to traditional drug delivery methods, such as oral administration and injections. Iontophoresis, leveraging the use of electrical current, provides a mechanism for precise control over drug dosing, making it particularly well-suited for the delivery of small, charged molecules. On the other hand, sonophoresis, which employs ultrasound waves, demonstrates the capability to effectively deliver a broader range of drugs, including both hydrophilic and hydrophobic compounds, and critically, large macromolecules. The potential for synergistic effects through the combined use of iontophoresis and sonophoresis, alongside ongoing advancements in the fields of nanotechnology and microfabrication, paves the way for further enhancements in transdermal drug delivery. Looking ahead, future research endeavors should prioritize the development of wearable and smart transdermal patches, the exploration of innovative combination therapies, and the expansion of the range of drugs that can be effectively delivered through these advanced methodologies.

REFERENCE

1. Wang Y, Thakur R, Fan Q, Michniak B. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur J Pharm Biopharm. 2005 Jul;60[2]:179-91. doi: 10.1016/j.ejpb.2004.12.008. PMID: 15939232.
2. Escobar-Chávez JJ, Bonilla-Martínez D, Villegas-González MA, Rodríguez-Cruz IM, Domínguez-Delgado CL. The use of sonophoresis in the administration of drugs throughout the skin. J Pharm Pharm Sci. 2009;12[1]:88-115. doi: 10.18433/j3c30d. PMID: 19470295.
3. Dixit N, Bali V, Baboota S, Ahuja A, Ali J. Iontophoresis - an approach for controlled drug delivery: a review. Curr Drug Deliv. 2007 Jan;4[1]:1-10. doi: 10.2174/156720181070401001. PMID: 17269912.
4. Goyal AK, Singh R, Chauhan G, Rath G. Non-invasive systemic drug delivery through mucosal routes. Artif Cells Nanomed Biotechnol. 2018;46[sup2]:539-551. doi: 10.1080/21691401.2018.1463230. Epub 2018 Apr 24. PMID: 29687750.
5. Park D, Park H, Seo J, Lee S. Sonophoresis in transdermal drug deliverys. Ultrasonics. 2014 Jan;54[1]:56-65. doi: 10.1016/j.ultras.2013.07.007. Epub 2013 Jul 16. PMID: 23899825.
6. Giannola LI, Sutera FM, De Caro V. Physical methods to promote drug delivery on mucosal tissues of the oral cavity. Expert Opin Drug Deliv. 2013 Oct;10[10]:1449-62. doi: 10.1517/17425247.2013.809061. Epub 2013 Jun 27. PMID: 23802558.

7. Mitragotri S, Blankschtein D, Langer R. Transdermal drug delivery using low-frequency sonophoresis. Pharm Res. 1996 Mar;13[3]:411-20. doi: 10.1023/a:1016096626810. PMID: 8692734
8. Herwadkar A, Banga AK. An update on the application of physical technologies to enhance intradermal and transdermal drug delivery. Ther Deliv. 2012 Mar;3[3]:339-55. doi: 10.4155/tde.12.1. PMID: 22833994.
9. . Z. Yu, W.B. Ying, D. Pravarthana, Y.Y. Li, G.Y. Mao, Y.W. Liu, C. Hu, W.X. Zhang, P.X. He, Z.C. Zhong, S.X. Qu, R.Y. Zhang, J. Shang, J. Zhu, R.-W. Li,Stretchable tactile sensor with high sensitivity and dynamic stability based on vertically aligned urchin-shaped nanoparticles,Materials Today Physics,Volume 14,2020,100219,
10. Dhote V, Bhatnagar P, Mishra PK, Mahajan SC, Mishra DK. Iontophoresis: a potential emergence of a transdermal drug delivery system. Sci Pharm. 2012 Jan-Mar;80[1]:1-28. doi: 10.3797/scipharm.1108-20. Epub 2011 Dec 13. PMID: 22396901; PMCID: PMC3293348.
11. Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci. 2010 Jan;99[1]:1-20. doi: 10.1002/jps.21793. PMID: 19499570.
12. Banga, A.K. New technologies to allow transdermal delivery of therapeutic proteins and small water-soluble drugs. Am J Drug Deliv 4, 221–230 [2006].
13. Dipak Kumar Gupta, Abdul Ahad, Mohd Aqil, Abdullah M. Al-Mohizea, Fahad I. Al-Jenoobi,Chapter 18 - Iontophoretic drug delivery: concepts, approaches, and applications vEditor[s]: Amit Kumar Nayak, Md Saquib Hasnain, Bibek Laha, Sabyasachi Maiti,Advanced and Modern Approaches for Drug Delivery,Academic Press,2023,Pages 515-546,
14. Giannola LI, Sutera FM, De Caro V. Physical methods to promote drug delivery on mucosal tissues of the oral cavity. Expert Opin Drug Deliv. 2013 Oct;10[10]:1449-62. doi: 10.1517/17425247.2013.809061. Epub 2013 Jun 27. PMID: 23802558.
15. Rao R, Nanda S. Sonophoresis: recent advancements and future trends. J Pharm Pharmacol. 2009 Jun;61[6]:689-705. doi: 10.1211/jpp.61.06.0001. PMID: 19505359.
16. Marathe D, Bhuvanashree VS, Mehta CH, T A, Nayak UY. Low-Frequency Sonophoresis: A Promising Strategy for Enhanced Transdermal Delivery. Adv Pharmacol Pharm Sci. 2024 Jun 5;2024:1247450. doi: 10.1155/2024/1247450. PMID: 38938593; PMCID: PMC11208788.
17. Petrilli, Raquel & Lopez, Renata. [2018]. Physical methods for topical skin drug delivery: Concepts and applications. Brazilian Journal of Pharmaceutical Sciences. 54. 10.1590/s2175-97902018000001008.
18. Byl NN. The use of ultrasound as an enhancer for transcutaneous drug delivery: phonophoresis. Phys Ther. 1995 Jun;75[6]:539-53. doi: 10.1093/ptj/75.6.539. PMID: 7770499.

19. Mitragotri, Samir. [2017]. Sonophoresis: Ultrasound-Mediated Transdermal Drug Delivery. 10.1007/978-3-662-53273-7_1.
20. Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci. 2010 Jan;99[1]:1-20. doi: 10.1002/jps.21793. PMID: 19499570.
21. Raut YB, Jundale NS. Review on Herbal Drugs Used in Transdermal Drug Delivery System. IJPRD, 2025.
22. Stefanache A, Huzum R, Sekeroglu N, Hancianu M. Modulating Polyphenol Activity with Metal Ions: Insights into Dermatological Applications. Preprints, 2025.
23. Almeida C, Roque R, Vieira J, Júlio A, Saraiva N. Lipid Extract from Black Soldier Fly Larvae: A High-Value Excipient for Solid Lipid Nanoparticles. International Journal of Pharmaceutics, 2024.
24. Ribeiro A, Pereira-Leite C, Rosado C, Aruci E. Enhancing Transcutaneous Drug Delivery: Advanced Perspectives on Skin Models. JID Innovations, 2025.
25. Steyn JD, Haasbroek-Pheiffer A, Pheiffer W. Evaluation of Drug Permeation Enhancement by Using In Vitro and Ex Vivo Models. PubMed, 2025.
26. Thakur N, Thakur S, Singh YP, Prasad S. A Current Review on Transdermal Delivery of Protein and Peptides. Letters in Drug Design & Discovery, 2025.
27. Moghaddam AV, Hashemi S, Abedin S. Dermal and Transdermal Novel Drug Delivery Systems. Book Chapter, 2025. Available at: https://books.google.com/books?hl=en&id=Ns07EQAAQBAJ.
28. Zhan W, Benbrook N. Mathematical Modelling of Hollow Microneedle-Mediated Transdermal Drug Delivery. Springer, 2025.
29. Saini P, Mandal RK, Dubey A, Pal R. Recent Advances in Transdermal Drug Delivery Systems. Journal of Pharma Insights and Research, 2024.
30. Lin ZC, Chang YT, Lin TJ. Novel Strategies in Topical Delivery for Psoriasis Treatment: Nanocarriers and Energy-Driven Approaches. Expert Opinion on Drug Delivery, 2025.
31. Datta D, Bandi SP, Janardhanam LSL, Colaco V. Extracellular Vesicles for Ophthalmic and Dermal Ailments. Elsevier, 2025.
32. Barbosa AI, Yousef I, Lima SAC, Reis S. Hybrid Hydrogels Incorporating Nanostructured Lipid Carriers: An Approach for Enhanced Local Delivery of Betamethasone in Atopic Dermatitis Therapy. SSRN, 2025.
33. Wei B, Wei M, Huang H, Fan T, Zhang Z. Mesenchymal Stem Cell-Derived Exosomes: A Promising Therapeutic Strategy for Age-Related Diseases. Wiley Online Library, 2024.
34. Wang T, Liu H, Li M, Ji Z, Zhang X, Wang N. Microneedle-Based Nanodrugs for Tumor Immunotherapy. Journal of Controlled Release, 2025.
35. Hulimane Shivaswamy R, Binulal P, Benoy A. Microneedles as a Promising Technology for Disease Monitoring and Drug Delivery: A Review. ACS Materials, 2024.
36. Van de Walle A, Zhang Y, Polini A. Micro and Nanoparticles for Regenerative Medicine. Frontiers in Bioengineering and Biotechnology, 2025.

37. Yu H, Gao Y, Xu T, Wang Y, Hu Y, Yin S, Qin Z. Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research. Pharmaceutics, 2025.
38. Cheng S, Ding J, Xu B, Wang Y, Shen X, Xia Y. G[1-5]-EM2, a Multi-Targeted Agonist to Opioid and Growth Hormone Secretagogue Receptors Exhibited Nontolerance Forming Antinociceptive Effects in a Mouse Model. European Journal of Pharmacology, 2025.
39. Tahmasbi F, Eslami S. Investigating iontophoresis as a therapeutic approach for Peyronie's disease: a systematic review. Sexual Medicine Reviews. 2025;13[1]:41.
40. Kannan RV, Tony LM. Iontophoresis in transdermal drug delivery. Proceedings of the International Conference on Recent Advances in Energy-efficient Computing and Communication. 2019.
41. Hasan M, Khatun A, Kogure K. Iontophoresis of biological macromolecular drugs. Pharmaceutics. 2022;14[3]:525.
42. Pikal MJ. The role of electroosmotic flow in transdermal iontophoresis. Adv Drug Deliv Rev. 2001;46[1-3]:281-305.
43. Singh P, Maibach H. Iontophoresis: Basic principles and applications. Crit Rev Ther Drug Carrier Syst. 1994;11[2-3]:161-213.
44. Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004;56[5]:619-58.
45. Wang Y, Zeng L, Song W, Liu J. Influencing factors and drug application of iontophoresis in transdermal drug delivery. Drug Delivery and Translational Research. 2022;12[4]:1121-33.
46. Yerworth RJ, Bayford RH, Holder DS. Iontophoretic delivery of lidocaine: Experimental and simulation studies. Physiol Meas. 2005;26[1]:31-42.
47. Eljarrat-Binstock E, Domb AJ. Iontophoresis: A non-invasive ocular drug delivery. J Control Release. 2006;110[3]:479-89.
48. Goh CL. Treatment of palmar hyperhidrosis using iontophoresis with tap water, normal saline, and 0.05% glycopyrrolate solution. Acta Derm Venereol. 1989;69[4]:345-8.
49. Costello CT, Jeske AH. Iontophoresis: Applications in transdermal medication delivery. Phys Ther. 1995;75[6]:554-63.
50. Pillai O, Panchagnula R. Transdermal iontophoresis of insulin: Mechanisms and considerations. J Control Release. 2003;89[1]:107-18.
51. Dhote V, Bhatnagar P, Mishra PK. Iontophoresis: a potential emergence of a transdermal drug delivery system. Scientia Pharmaceutica. 2011;80[1]:1-12.
52. Kanikkannan N. BioDrugs. Iontophoresis-based transdermal delivery systems. 2002;16[5]:339-47.
53. Fang JY, Sung KC, Lin HH, Chen HC. Effect of ultrasound and iontophoresis on the percutaneous absorption of flurbiprofen in vitro and in vivo. Int J Pharm. 1999;192[1]:33-43.
54. Scott LJ. Fentanyl iontophoretic transdermal system: a review in acute postoperative pain. Clin Drug Investig. 2016;36[7]:553-65.

55. Cammarano A, Dello Iacono S, Meglio C, Nicolais L. Advances in transdermal drug delivery systems: a bibliometric and patent analysis. *Pharmaceutics*. 2023;15[12]:2762.
56. Liu T, Chen K, Yan Z, Wang Q. Comparative study of permeation effects between vibrating microneedle and low-frequency sonophoresis systems. *Drug Deliv Transl Res*. 2024.
57. Narala S, Youssef AAA, Kolimi P. A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery. *Nanotechnology Reviews*. 2023.
58. Rao R, Nanda S. Sonophoresis: recent advancements and future trends. *J Pharm Pharmacol*. 2009;61[6]:689–703.
59. Jeong WY, Kwon M, Choi HE, Kim KS. Recent advances in transdermal drug delivery systems: A review. *Biomaterials Research*. 2021;25[1]:10.
60. Gao Y, Du L, Li Q, Zhu L, Yang M, Wang X. How physical techniques improve the transdermal permeation of therapeutics: A review. *Medicine*. 2022;101[27]:e29007.
61. Nguyen HX, Banga AK. Electrically and ultrasonically enhanced transdermal delivery of methotrexate. *Pharmaceutics*. 2018;10[3]:117.
62. Kim YC, Park J, Lee H, Lim GS. Enhanced transdermal drug delivery by sonophoresis and simultaneous application of sonophoresis and iontophoresis. *AAPS PharmSciTech*. 2019;20[8]:1309.
63. Tawfik MA, Mohamed MI, Tadros MI, El-Helaly SN. Low-frequency sonophoresis as an active approach to potentiate the transdermal delivery of agomelatine-loaded novasomes: design, optimization, and pharmacokinetic profiling in rabbits. *AAPS PharmSciTech*. 2021;22[1]:147.
64. Banga AK. New technologies to allow transdermal delivery of therapeutic proteins and small water-soluble drugs. *Am J Drug Deliv*. 2006;4[4]:221–32.
65. Mitragotri S. Sonophoresis: ultrasound-mediated transdermal drug delivery. *Percutaneous Penetration Enhancers Physical Methods*. 2017;1[2]:45–62.
66. Park D, Song G, Jo Y, Won J, Son T, Cha O, Kim J. Sonophoresis using ultrasound contrast agents: dependence on concentration. *PLoS One*. 2016;11[6]:e0157707.
67. Vaseem RS, D'Cruz A, Shetty S, et al. Transdermal drug delivery systems: a focused review of the physical methods of permeation enhancement. *Asian J Pharm Sci*. 2023;14[1]:67-79.
68. Martínez-Segoviano IJ, Ganem-Rondero A. Enhancement of the transdermal delivery of zidovudine by pretreating the skin with two physical enhancers: microneedles and sonophoresis. *Iran J Pharm Res*. 2021;20[1]:97-112.
69. Guy RH. Transdermal drug delivery. *Drug Delivery*. 2010;19[3]:78-90.
70. Dhote V, Bhatnagar P, Mishra PK. Iontophoresis: a potential emergence of a transdermal drug delivery system. *Scientia Pharmaceutica*. 2011;80[1]:1-12.
71. Nguyen HX, Banga AK. Electrically and ultrasonically enhanced transdermal delivery of methotrexate. *Pharmaceutics*. 2018;10[3]:117.

72. Martin-Vega FJ, Vinolo-Gil MJ. Use of sonophoresis with corticosteroids in carpal tunnel syndrome: Systematic review and meta-analysis. *J Pers Med*. 2022;12[7]:1160.
73. Rao R, Nanda S. Sonophoresis: Recent advancements and future trends. *J Pharm Pharmacol*. 2009;61[6]:689–703.
74. Wang Y, Zeng L, Song W, Liu J. Influencing factors and drug application of iontophoresis in transdermal drug delivery. *Drug Deliv Transl Res*. 2022;12[4]:1121-33.
75. Akhtar N, Singh V, Yusuf M, Khan RA. Non-invasive drug delivery technology: Development and current status. *Biomed Eng Transl Med*. 2020;1[2]:93-108.
76. Park D, Song G, Jo Y, Won J, Son T, Cha O, Kim J. Sonophoresis using ultrasound contrast agents: Dependence on concentration. *PLoS One*. 2016;11[6]:e0157707.
77. Kumar L, Verma S, Singh M, Chalotra T. Advanced drug delivery systems for transdermal delivery of non-steroidal anti-inflammatory drugs. *Curr Drug Deliv*. 2018;15[4]:317-29.
78. Choi JH, Shin EJ, Jeong KH, Shin MK. Comparative analysis of CO_2 fractional laser and sonophoresis for transdermal drug penetration. *Lasers Med Sci*. 2017;32[5]:1057-64.
79. Perez VL, Wirostko B, Korenfeld M, From S. Ophthalmic drug delivery using iontophoresis. *J Ocul Pharmacol Ther*. 2020;36[5]:341-52.
80. Dhote V, Bhatnagar P, Mishra PK. Iontophoresis: A potential emergence of a transdermal drug delivery system. *Scientia Pharmaceutica*. 2011;80[1]:1-12.
81. Ibrahim NA, Hamdy HA, Elbanna RHM, Aboelsoud MA. Transdermal iontophoresis versus high-power pain threshold ultrasound in mechanical neck pain: A randomized controlled trial. *J Orthop Surg Res*. 2024;19[1]:50.
82. Li T, Liu S, Bao X, Zhang S, Zhang H, Lu X. The study of ultrasound and iontophoresis on oxaprozin transdermal penetration using surface-enhanced Raman spectroscopy. *Drug Deliv Transl Res*. 2020;10[3]:655-66.
83. Son T, Park D, Song G, Jo Y, Won J, Kim J. Efficiency comparison of sonophoresis and iontophoresis for transdermal drug delivery. *PLOS One*. 2016;11[6]:e0157707.
84. Adedapo AA, Yusuf AA. *Iontophoresis: An emerging approach to transdermal drug delivery*.
85. Hasan M, Khatun A, Kogure K. *Intradermal delivery of naked mRNA vaccines via iontophoresis*. *Pharmaceutics*. 2023;15[12]:2678.
86. Sivadasan D, Madkhali OA. *Transdermal drug delivery systems—A comprehensive review*. *Pharmaceuticals*. 2024;17[10]:1346.
87. Siafaka PI, Özcan Bülbül E, Okur ME, Karantas ID. *The application of nanogels as efficient drug delivery platforms for dermal/transdermal delivery*. *Gels*. 2023;9[9]:753.

88. Dhote V, Bhatnagar P, Mishra PK. *Iontophoresis: a potential emergence of a transdermal drug delivery system*. *Scientia Pharmaceutica*. 2011.

89. Malayandi R, Hmingthansanga V, Kumar L, et al. *Chitosan-based formulations for enhanced topical, transdermal, and ocular drug delivery*. *Springer*. 2025.

90. Ferraz R, Teixeira C. *The emerging role of ionic liquid-based approaches for enhanced skin permeation of bioactive molecules*. *International Journal of Molecular Sciences*. 2021;22[21]:11991.

91. Banga AK. *New technologies to allow transdermal delivery of therapeutic proteins and small water-soluble drugs*. *American Journal of Drug Delivery*. 2006.

92. Lengert EV, Tuchin VV. *Nanotechnology-based strategies for enhanced intra- and transdermal delivery of antifungal drugs*. *Skin Pharmacology and Physiology*. 2020.

93. Bariya SH, Mehta TA. *Microneedles: an emerging transdermal drug delivery system*. *Journal of Pharmacy and Pharmacology*. 2012.

94. Patel D, Wairkar S. *Recent advances in cyclosporine drug delivery: challenges and opportunities*. *Drug Delivery and Translational Research*. 2019.

95. Hirvonen J. *Topical iontophoretic delivery: progress to date and therapeutic potential*. *American Journal of Drug Delivery*. 2005.

96. Patel A, Cholkar K, Agrahari V, Mitra AK. *Ocular drug delivery systems: An overview*. *World Journal of Pharmacology*. 2013;2[2]:47-64.

97. Sivakumar SM, Banga AK. *Transdermal delivery of drugs for the treatment of systemic and local diseases*. *Expert Opinion on Drug Delivery*. 2018;15[6]:475-493.

98. Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare OP. *Sonophoresis for the transdermal drug delivery of an anti-cancer agent: Influence of ultrasound intensity and duration*. *European Journal of Pharmaceutics and Biopharmaceutics*. 2018;128:243-255.

99. Cheng T, Tai Z, Shen M, et al. Advance and challenges in the treatment of skin diseases with the transdermal drug delivery system. *Pharmaceutics*. 2023;15[8]:2165.

100. Madkhali OA, Sivadasan D. The design features, quality by design approach, characterization, therapeutic applications, and clinical considerations of transdermal drug delivery. *Pharmaceuticals*. 2024;17[10]:1346.

101. Uddin SMZ, Komatsu DE, Motyka T. Low-intensity continuous ultrasound therapies—a systematic review of current state-of-the-art and future perspectives. *J Clin Med*. 2021;10[12]:2698.

102. Cammarano A, Dello Iacono S, Meglio C, Nicolais L. Advances in transdermal drug delivery systems: a bibliometric and patent analysis. *Pharmaceutics*. 2023;15[12]:2762.
103. Ji M, Liu G, Cui Y, Zhao P. Safety and efficacy concerns of modern strategies of local anesthetics delivery. *3 Biotech*. 2020;10[5]:45.
104. Akhtar N, Singh V, Yusuf M, Khan RA. Non-invasive drug delivery technology: Development and current status of transdermal drug delivery devices, techniques, and biomedical applications. *Biomed Eng Technol*. 2020;65[3]:201-12.
105. Kumar V, Praveen N, Kewlani P, et al. Transdermal drug delivery systems. *Adv Drug Deliv Sci*. 2023;44[6]:115-30.
106. Singh P, Muhammad I, Nelson NE, Tran KTM. Transdermal delivery for gene therapy. *Drug Deliv Transl Res*. 2022;12[5]:1101-15.
107. Banga AK. New technologies to allow transdermal delivery of therapeutic proteins and small water-soluble drugs. *Am J Drug Deliv*. 2006;4[4]:189-202.
108. Kalluri H, Banga AK. Transdermal delivery of proteins. *AAPS PharmSciTech*. 2011;12[3]:308-21.
109. Wang Y, Zeng L, Song W, Liu J. Influencing factors and drug application of iontophoresis in transdermal drug delivery: an overview of recent progress. *Drug Deliv Transl Res*. 2022;12[4]:851-65.
110. Hirvonen J. Topical iontophoretic delivery: progress to date and therapeutic potential. *Am J Drug Deliv*. 2005;3[2]:85-101.
111. Lin CY, Lin ZC, Chang YT, Lin TJ. Novel strategies in topical delivery for psoriasis treatment: nanocarriers and energy-driven approaches. *Expert Opin Drug Deliv*. 2025;22[1]:45-67.
112. Murrell GAC. Treatment of tendinopathy: what works, what does not, and what is on the horizon. *Clin Orthop Relat Res*. 2008;466[7]:1539-54.
113. Ferraz R, Teixeira C. *The emerging role of ionic liquid-based approaches for enhanced skin permeation of bioactive molecules: a snapshot of the past couple of years*. *Int J Mol Sci*. 2021;22[21]:11991.
114. Ramesh R, Banga AK. *Nanocarrier-based transdermal drug delivery: advances and clinical potential*. *Expert Opin Drug Deliv*. 2022;19[4]:457-75.
115. Singh R, Kaur T. *Microfabrication in iontophoretic drug delivery: Advances and future perspectives*. *J Control Release*. 2023;354:47-65.
116. Wang M, Zhao Z, Liu Y, et al. *Microbubble-assisted sonophoresis for transdermal drug delivery: Mechanisms and applications*. *Ultrasound Med Biol*. 2022;48[5]:993-1005.
117. Zhang L, Zhou J, Xu B, et al. *Wearable transdermal patches for precision drug delivery: Current status and future perspectives*. *Adv Drug Deliv Rev*. 2023;192:114629.
118. Lee H, Song C, Baik S, et al. *A wireless smart patch for continuous glucose monitoring and insulin delivery*. *Sci Adv*. 2022;8[19]:eabm2447.

119. Seong D, Park J, Kim J. *Wearable ultrasound patches for non-invasive transdermal drug delivery: A review of materials and technologies*. *Adv Funct Mater*. 2023;33[17]:2208356.
120. Cormier M, Johnson B, Ameri M. *Development and clinical evaluation of a novel iontophoretic drug delivery patch*. *J Pharm Sci*. 2021;110[9]:3011-21.
121. Tan J, Liu D, He Y. *Wearable sonophoretic drug delivery: A next-generation transdermal therapeutic approach*. *Nano Today*. 2023;48:101805.
122. Donnelly RF, Morrow DIJ, Singh TRR. *Microneedle-mediated transdermal and intradermal drug delivery*. *Drug Deliv Transl Res*. 2023;13[3]:587-601.
123. Prausnitz MR, Langer R. *Transdermal delivery of macromolecules using microneedles*. *Nat Biotechnol*. 2023;41[1]:45-57.
124. Hwang H, Choi J. *Nanocarrier-mediated sonophoretic drug delivery in oncology: Advances and challenges*. *Cancers*. 2022;14[8]:1892.
125. Bose S, Udaykumar HS. *Multimodal transdermal drug delivery systems: Future directions and applications*. *Trends Pharmacol Sci*. 2024;45[2]:157-71.